Teva to buy U.S. drug developer Auspex Pharma for $3.5 billion

TEL AVIV (Reuters) – Israel’s Teva Pharmaceutical Industries said it would buy U.S. neurology drug company Auspex Pharmaceuticals Inc for an equity value of $3.5 billion to boost its portfolio of treatments for the central nervous system.


Source: Business

Leave a Reply

Your email address will not be published. Required fields are marked *

17 − 3 =